GSM gold starGSM Global
中文版 · Chinese

FDA Clears Oculis' Privosegtor IND to Advance Clinical Development in Acute Multiple Sclerosis Relapses

Monday, November 16, 2026 · Health · GSM News

Oculis Holding AG (Nasdaq: OCS), a Swiss biopharmaceutical company, announced on November 16 that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its candidate Privosegtor for the treatment of acute multiple sclerosis (MS) relapses, allowing clinical development to begin in the new indication.

According to the company, in pre-IND feedback the FDA Division of Neurology-2 confirmed that Oculis can cross-reference data from the open Privosegtor ophthalmology-related IND. The FDA also supported the proposed clinical development strategy, which would include MS patients who experience optic neuritis as well as other types of relapses, such as ambulatory relapses, with a primary endpoint as early as three months and the same dose used in PIONEER-1, 3 mg/kg daily for five days.

The expansion builds on the Phase 2 ACUITY study in optic neuritis, in which Privosegtor showed a neuroprotective effect, improved visual function, preserved the retinal ganglion cell layer, and reduced blood levels of neurofilament light chain, a biomarker of axonal injury, and glial fibrillary acidic protein, a biomarker of astrocytic activation. Oculis Chief Executive Officer Dr. Riad Sherif said the IND clearance marks Privosegtor's advance from optic neuritis into acute MS relapses, a high-unmet-need setting with no currently approved neuroprotective therapies.

Multiple sclerosis is a chronic autoimmune disease of the central nervous system affecting approximately 2.8 million people worldwide, including around 850,000 in the United States, where an estimated 170,000 relapses occur each year. Current treatment of acute relapses relies mainly on high-dose corticosteroids to shorten the episode, while long-term immunomodulators reduce relapse frequency; neither approach has been proven to directly protect neurons and axons. Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency, as well as Orphan Drug designation from both agencies for optic neuritis, and is being evaluated in the PIONEER registrational program. It remains an investigational drug and has not been approved in any country.

Oculis is headquartered in Zug, Switzerland, with operations in the United States and Europe. The company plans to host an R&D Day on December 8, 2026, to provide further updates on the development program for Privosegtor in acute MS relapses and on the PIONEER program in optic neuropathies.

(Source: Oculis)

Source: Oculis

Published by GSM · USA (original Chinese edition)

Photo: 图:美国食品药品监管局(FDA)总部大楼入口。FDA 官方图,公共领域,经 Wikimedia Commons。 / Photo: Entrance of the U.S. Food and Drug Administration headquarters. FDA official photo, public domain, via Wikimedia Commons.

Latest in Health